Vaccinex, Inc. Reports Executive and Director Changes
Ticker: VCNX · Form: 8-K · Filed: Mar 4, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Mar 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Vaccinex leadership shakeup: new directors elected, some officers/directors out, effective Feb 27.
AI Summary
On February 27, 2024, Vaccinex, Inc. filed an 8-K report detailing changes in its executive and director positions. The filing indicates the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific details regarding the individuals involved and the exact nature of the compensatory arrangements were not fully elaborated in the provided text, but the changes are effective as of February 27, 2024.
Why It Matters
Changes in a company's leadership and board of directors can signal shifts in strategy, operational focus, or governance, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive and director roles can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- 001-38624 (company_id) — Commission File Number
- 16-1603202 (company_id) — IRS Employer Identification No.
- February 27, 2024 (date) — Date of earliest event reported
FAQ
What specific roles have been affected by the departures of officers and directors?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not specify the exact roles or names of the individuals departing in the provided text.
Who are the newly elected directors?
The filing states that directors have been elected, but the names of the newly elected directors are not provided in the excerpt.
What are the key changes in compensatory arrangements?
The filing mentions updates to 'Compensatory Arrangements of Certain Officers' but does not detail the specific changes or the amounts involved in the provided text.
What is the effective date of these reported changes?
The earliest event reported, including the departures and elections, is dated February 27, 2024.
What is Vaccinex, Inc.'s primary business according to the filing?
Vaccinex, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-03-04 16:19:18
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
Filing Documents
- d823677d8k.htm (8-K) — 23KB
- 0001193125-24-057888.txt ( ) — 138KB
- vcnx-20240227.xsd (EX-101.SCH) — 3KB
- vcnx-20240227_lab.xml (EX-101.LAB) — 17KB
- vcnx-20240227_pre.xml (EX-101.PRE) — 11KB
- d823677d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VACCINEX, INC. Date: March 4, 2024 By: /s/ Scott Royer Scott Royer Chief Financial Officer